Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 313

1.

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.

List JF, Whaley JM.

Kidney Int Suppl. 2011 Mar;(120):S20-7. doi: 10.1038/ki.2010.512. Review.

PMID:
21358698
2.

Renal glucose reabsorption inhibitors to treat diabetes.

Bailey CJ.

Trends Pharmacol Sci. 2011 Feb;32(2):63-71. doi: 10.1016/j.tips.2010.11.011. Epub 2011 Jan 4. Review.

PMID:
21211857
3.
4.

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Kurosaki E, Ogasawara H.

Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4. Review.

PMID:
23563279
5.

Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.

Raskin P.

Diabetes Metab Res Rev. 2013 Jul;29(5):347-56. doi: 10.1002/dmrr.2403. Review.

PMID:
23463735
6.

SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.

Jabbour SA.

Postgrad Med. 2014 Jan;126(1):111-7. doi: 10.3810/pgm.2014.01.2731. Review.

PMID:
24393758
7.

SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.

Kilov G, Leow S, Thomas M.

Aust Fam Physician. 2013 Oct;42(10):706-10. Review.

8.

Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.

Davidson JA, Kuritzky L.

Postgrad Med. 2014 Oct;126(6):33-48. doi: 10.3810/pgm.2014.10.2819. Review.

PMID:
25414933
9.
10.

Sodium glucose cotransporter 2 and the diabetic kidney.

Komala MG, Panchapakesan U, Pollock C, Mather A.

Curr Opin Nephrol Hypertens. 2013 Jan;22(1):113-9. doi: 10.1097/MNH.0b013e32835a17ae. Review.

PMID:
23042029
11.

SGLT2 inhibitors: molecular design and potential differences in effect.

Isaji M.

Kidney Int Suppl. 2011 Mar;(120):S14-9. doi: 10.1038/ki.2010.511. Review.

PMID:
21358697
12.

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

Liu JJ, Lee T, DeFronzo RA.

Diabetes. 2012 Sep;61(9):2199-204. doi: 10.2337/db12-0052.

13.

[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].

Albarrán OG, Ampudia-Blasco FJ.

Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. doi: 10.1016/S0025-7753(13)70062-9. Review. Spanish.

PMID:
24444523
14.

Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.

Chen LH, Leung PS.

Diabetes Obes Metab. 2013 May;15(5):392-402. doi: 10.1111/dom.12064. Epub 2013 Feb 6. Review.

PMID:
23331516
15.

Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.

Gallo LA, Wright EM, Vallon V.

Diab Vasc Dis Res. 2015 Mar;12(2):78-89. doi: 10.1177/1479164114561992. Epub 2015 Jan 23. Review.

PMID:
25616707
16.

SGLT2 inhibitors.

Dardi I, Kouvatsos T, Jabbour SA.

Biochem Pharmacol. 2016 Feb 1;101:27-39. doi: 10.1016/j.bcp.2015.09.005. Epub 2015 Sep 8.

PMID:
26362302
17.

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.

Jabbour SA, Whaley JM, Tirmenstein M, Poucher SM, Reilly TP, Boulton DW, Saye J, List JF, Parikh S.

Postgrad Med. 2012 Jul;124(4):62-73. doi: 10.3810/pgm.2012.07.2569. Review.

PMID:
22913895
18.

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.

Neumiller JJ, White JR Jr, Campbell RK.

Drugs. 2010 Mar 5;70(4):377-85. doi: 10.2165/11318680-000000000-00000. Review.

PMID:
20205482
19.

A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'.

Chan HW, Ashan B, Jayasekera P, Collier A, Ghosh S.

Diabetes Metab Syndr. 2012 Oct-Dec;6(4):224-8. doi: 10.1016/j.dsx.2012.08.003. Epub 2012 Oct 16. Review.

PMID:
23199545

Supplemental Content

Support Center